Bone Biologics Statistics
Total Valuation
Bone Biologics has a market cap or net worth of $1.22 million. The enterprise value is -$2.01 million.
| Market Cap | 1.22M |
| Enterprise Value | -2.01M |
Important Dates
The next estimated earnings date is Monday, August 12, 2024, before market open.
| Earnings Date | Aug 12, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
Bone Biologics has 1.10 million shares outstanding. The number of shares has increased by 883.36% in one year.
| Shares Outstanding | 1.10M |
| Shares Change (YoY) | +883.36% |
| Shares Change (QoQ) | +151.17% |
| Owned by Insiders (%) | 6.51% |
| Owned by Institutions (%) | 4.70% |
| Float | 1.01M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 0.33 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 23.32, with zero debt.
| Current Ratio | 23.32 |
| Quick Ratio | n/a |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -152.00% and return on invested capital (ROIC) is -195.49%.
| Return on Equity (ROE) | -152.00% |
| Return on Assets (ROA) | -121.00% |
| Return on Capital (ROIC) | -195.49% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$3.05M |
| Employee Count | 2 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -89.49% in the last 52 weeks. The beta is 0.67, so Bone Biologics's price volatility has been lower than the market average.
| Beta (5Y) | 0.67 |
| 52-Week Price Change | -89.49% |
| 50-Day Moving Average | 1.47 |
| 200-Day Moving Average | 2.87 |
| Relative Strength Index (RSI) | 35.36 |
| Average Volume (20 Days) | 57,701 |
Short Selling Information
The latest short interest is 818, so 0.07% of the outstanding shares have been sold short.
| Short Interest | 818 |
| Short Previous Month | 21,746 |
| Short % of Shares Out | 0.07% |
| Short % of Float | 0.08% |
| Short Ratio (days to cover) | 0.01 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -7.18M |
| Pretax Income | -6.10M |
| Net Income | -6.10M |
| EBITDA | -6.10M |
| EBIT | -6.10M |
| Earnings Per Share (EPS) | -$16.34 |
Balance Sheet
The company has $3.23 million in cash and no debt, giving a net cash position of $3.23 million or $2.93 per share.
| Cash & Cash Equivalents | 3.23M |
| Total Debt | n/a |
| Net Cash | 3.23M |
| Net Cash Per Share | $2.93 |
| Equity (Book Value) | 3.67M |
| Book Value Per Share | 3.34 |
| Working Capital | 3.67M |
Cash Flow
| Operating Cash Flow | -9.51M |
| Capital Expenditures | n/a |
| Free Cash Flow | -9.51M |
| FCF Per Share | -$14.39 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Bone Biologics does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -883.36% |
| Shareholder Yield | -883.36% |
| Earnings Yield | -499.76% |
| FCF Yield | -778.47% |
Analyst Forecast
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock Splits
The last stock split was on December 20, 2023. It was a reverse split with a ratio of 1:8.
| Last Split Date | Dec 20, 2023 |
| Split Type | Reverse |
| Split Ratio | 1:8 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |